Form SCHEDULE 13G - Statement of Beneficial Ownership by Certain Investors:
SEC Accession No. 0000902664-25-002397
Filing Date
2025-05-15
Accepted
2025-05-15 16:14:25
Documents
2

Document Format Files

Seq Description Document Type Size
1 primary_doc.html SCHEDULE 13G  
1 primary_doc.xml SCHEDULE 13G 9048
2 JOINT FILING AGREEMENT p25-1169exhibit99_1.htm EX-99.1 4749
  Complete submission text file 0000902664-25-002397.txt   15592
Mailing Address 7 TIMES SQUARE 43RD FLOOR NEW YORK NY 10036
Business Address 7 TIMES SQUARE 43RD FLOOR NEW YORK NY 10036 929-999-4055
Dianthus Therapeutics, Inc. /DE/ (Subject) CIK: 0001690585 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SCHEDULE 13G | Act: 34 | File No.: 005-90538 | Film No.: 25953209
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)

Mailing Address 632 BROADWAY SUITE 602 NEW YORK NY 10012
Business Address 632 BROADWAY SUITE 602 NEW YORK NY 10012 6469894000
Vestal Point Capital, LP (Filed by) CIK: 0001974915 (see all company filings)

EIN.: 922296021 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SCHEDULE 13G